Pharmacokinetic considerations for targeted drug delivery

Advanced Drug Delivery Reviews

Volumn 65, Issue 1, 2013, Pages 139-147

  Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Chemical modified proteins; Drug delivery system; Liposomes; Macromolecular prodrugs; Nanoparticles; Pharmacokinetics; Targeted drug delivery; Tissue uptake clearance

Indexed keywords

BIODISTRIBUTIONS; DELIVERY SYSTEMS; DRUG CARRIER; DRUG DELIVERY SYSTEM; GENETICALLY MODIFIED; MACROMOLECULAR DRUGS; MODIFIED PROTEINS; PHARMACOKINETIC ANALYSIS; PHYSICOCHEMICAL PROPERTY; PRODRUGS; QUANTITATIVE INFORMATION; TARGETED DRUG DELIVERY; THERAPEUTIC EFFICACY;

DRUG DELIVERY; LIPOSOMES; MACROMOLECULES; NANOPARTICLES; PROTEINS; TISSUE;

PHARMACOKINETICS;

CATALASE; DOXORUBICIN; DRUG CARRIER; HYBRID PROTEIN; PACLITAXEL; POLYMER; PRODRUG; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

BREAST CANCER; CHEMICAL MODIFICATION; COMPLEMENT ACTIVATION; CONTROLLED DRUG RELEASE; DNA MODIFICATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; GLOMERULUS FILTRATION; HUMAN; KAPOSI SARCOMA; MACROMOLECULE; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PERMEABILITY; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; TISSUE DISTRIBUTION; URINARY EXCRETION;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 84873273567     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.11.006     Document Type: Review

References (128)

1. Bischoff K.B., Dedrick R.L. Thiopental pharmacokinetics. J. Pharm. Sci. 1968, 57:1346-1351.
2. Bischoff K.B., Dedrick R.L., Zaharko D.S., Longstreth J.A. Methotrexate pharmacokinetics. J. Pharm. Sci. 1971, 60:1128-1133.
3. Rowland M., Benet L.Z., Graham G.G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1973, 1:123-136.
4. Takakura Y., Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. 1996, 13:820-831.
5. Nishikawa M., Takakura Y., Hashida M. Theoretical considerations involving the pharmacokinetics of plasmid DNA. Adv. Drug Deliv. Rev. 2005, 57:675-688.
6. Nishikawa M., Staud F., Takemura S., Takakura Y., Hashida M. Pharmacokinetic evaluation of biodistribution data obtained with radiolabeled proteins in mice. Biol. Pharm. Bull. 1999, 22:214-218.
7. Bohrer M.P., Baylis C., Humes H.D., Glassock R.J., Robertson C.R., Brenner B.M. Permselectivity of the glomerular capillary wall. Facilitated filtration of circulating polycations. J. Clin. Invest. 1978, 61:72-78.
8. Chang R.L., Deen W.M., Robertson C.R., Brenner B.M. Permselectivity of the glomerular capillary wall: III. Restricted transport of polyanions. Kidney Int. 1975, 8:212-218.
9. Wartiovaara J., Ofverstedt L.G., Khoshnoodi J., Zhang J., Mäkelä E., Sandin S., Ruotsalainen V., Cheng R.H., Jalanko H., Skoglund U., Tryggvason K. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J. Clin. Invest. 2004, 114:1475-1483.
10. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., Bawendi M.G., Frangioni J.V. Renal clearance of quantum dots. Nat. Biotechnol. 2007, 25:1165-1170.
11. Birn H., Christensen E.I. Renal albumin absorption in physiology and pathology. Kidney Int. 2006, 69:440-449.
12. Russo L.M., Sandoval R.M., McKee M., Osicka T.M., Collins A.B., Brown D., Molitoris B.A., Comper W.D. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int. 2007, 71:504-513.
13. Pisal D.S., Kosloski M.P., Balu-Iyer S.V. Delivery of therapeutic proteins. J. Pharm. Sci. 2010, 99:2557-2575.
14. Heathcote J., Zeuzem S. Pegylated interferon monotherapy for chronic hepatitis C. Semin. Liver Dis. 2004, 24(Suppl. 2):39-45.
15. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr. Pharm. Des. 2004, 10:1235-1244.
16. Yabe Y., Nishikawa M., Tamada A., Takakura Y., Hashida M. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. J. Pharmacol. Exp. Ther. 1999, 289:1176-1184.
17. Hyoudou K., Nishikawa M., Kobayashi Y., Kuramoto Y., Yamashita F., Hashida M. Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase. Clin. Exp. Metastasis 2006, 23:269-278.
18. Hyoudou K., Nishikawa M., Ikemura M., Kobayashi Y., Mendelsohn A., Miyazaki N., Tabata Y., Yamashita F., Hashida M. Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase. J. Control. Release 2009, 137:110-115.
19. Nishikawa M., Tamada A., Kumai H., Yamashita F., Hashida M. Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. Int. J. Cancer 2002, 99:474-479.
20. Ikemura M., Nishikawa M., Hyoudou K., Kobayashi Y., Yamashita F., Hashida M. Improvement of insulin resistance by removal of systemic hydrogen peroxide by PEGylated catalase in obese mice. Mol. Pharm. 2010, 7:2069-2076.
21. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
22. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzym. Regul. 2001, 41:189-207.
23. Igarashi R., Hoshino J., Ochiai A., Morizawa Y., Mizushima Y. Lecithinized superoxide dismutase enhances its pharmacologic potency by increasing its cell membrane affinity. J. Pharmacol. Exp. Ther. 1994, 271:1672-1677.
24. Ishihara T., Tanaka K., Tasaka Y., Namba T., Suzuki J., Okamoto S., Hibi T., Takenaga M., Igarashi R., Sato K., Mizushima Y., Mizushima T. Therapeutic effect of lecithinized superoxide dismutase against colitis. J. Pharmacol. Exp. Ther. 2009, 328:152-164.
25. Takenaga M., Ohta Y., Tokura Y., Hamaguchi A., Nakamura M., Okano H., Igarashi R. Lecithinized superoxide dismutase (PC-SOD) improved spinal cord injury-induced motor dysfunction through suppression of oxidative stress and enhancement of neurotrophic factor production. J. Control. Release 2006, 110:283-289.
26. Tomkin G.H. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. Curr. Opin. Mol. Ther. 2009, 11:579-588.
27. Rustgi V.K. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr. Med. Res. Opin. 2009, 25:991-1002.
28. Ikuta S., Chuang V.T., Ishima Y., Nakajou K., Furukawa M., Watanabe H., Maruyama T., Otagiri M. Albumin fusion of thioredoxin-the production and evaluation of its biological activity for potential therapeutic applications. J. Control. Release 2010, 147:17-23.
29. Stork R., Campigna E., Robert B., Müller D., Kontermann R.E. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J. Biol. Chem. 2009, 284:25612-25619.
30. Jing Y., Lu H., Wu K., Subramanian I.V., Ramakrishnan S. Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins. Int. J. Cancer 2011, 129:751-761.
31. Cao L., Du P., Jiang S.H., Jin G.H., Huang Q.L., Hua Z.C. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol. Cancer Ther. 2008, 7:851-861.
32. Poznansky M.J., Juliano R.L. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol. Rev. 1984, 36:277-336.
33. Djaldetti M., Salman H., Bergman M., Djaldetti R., Bessler H. Phagocytosis-the mighty weapon of the silent warriors. Microsc. Res. Tech. 2002, 57:421-431.
34. Opanasopit P., Nishikawa M., Hashida M. Factors affecting drug and gene delivery: effects of interaction with blood components. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19:191-233.
35. Cullis P.R., Chonn A., Semple S.C. Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv. Drug Deliv. Rev. 1998, 32:3-17.
36. Opanasopit P., Higuchi Y., Kawakami S., Yamashita F., Nishikawa M., Hashida M. Involvement of serum mannan binding proteins and mannose receptors in uptake of mannosylated liposomes by macrophages. Biochim. Biophys. Acta 2001, 1511:134-145.
37. Terada T., Nishikawa M., Yamashita F., Hashida M. Influence of cholesterol composition on the association of serum mannan-binding proteins with mannosylated liposomes. Biol. Pharm. Bull. 2006, 29:613-618.
38. Ogawara K., Furumoto K., Nagayama S., Minato K., Higaki K., Kai T., Kimura T. Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. J. Control. Release 2004, 100:451-455.
39. Maruyama K., Mori A., Bhadra S., Subbiah M.T., Huang L. Proteins and peptides bound to long-circulating liposomes. Biochim. Biophys. Acta 1991, 1070:246-252.
40. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J. Biol. Chem. 1992, 267:18759-18765.
41. Ogawara K., Yoshida M., Kubo J., Nishikawa M., Takakura Y., Hashida M., Higaki K., Kimura T. Mechanisms of hepatic disposition of polystyrene microspheres in rats: effects of serum depend on the sizes of microspheres. J. Control. Release 1999, 61:241-250.
42. Ayhan H., Tuncel A., Bor N., Pişkin E. Phagocytosis of monosize polystyrene-based microspheres having different size and surface properties. J. Biomater. Sci. Polym. Ed. 1995, 7:329-342.
43. Monopoli M.P., Walczyk D., Campbell A., Elia G., Lynch I., Bombelli F.B., Dawson K.A. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 2011, 133:2525-2534.
44. Lesniak A., Campbell A., Monopoli M.P., Lynch I., Salvati A., Dawson K.A. Serum heat inactivation affects protein corona composition and nanoparticle uptake. Biomaterials 2010, 31:9511-9518.
45. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol. Life Sci. 2009, 66:2873-2896.
46. Teeguarden J.G., Hinderliter P.M., Orr G., Thrall B.D., Pounds J.G. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol. Sci. 2007, 95:300-312.
47. Harashima H., Sakata K., Funato K., Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res. 1994, 11:402-406.
48. Vonarbourg A., Passirani C., Saulnier P., Simard P., Leroux J.C., Benoit J.P. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J. Biomed. Mater. Res. A 2006, 78:620-628.
49. Vonarbourg A., Passirani C., Saulnier P., Benoit J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006, 27:4356-4373.
50. Juliano R.L., Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem. Biophys. Res. Commun. 1975, 63:651-658.
51. Gregoriadis G., Ryman B.E. Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats. Biochem. J. 1972, 129:123-133.
52. Lee K.D., Pitas R.E., Papahadjopoulos D. Evidence that the scavenger receptor is not involved in the uptake of negatively charged liposomes by cells. Biochim. Biophys. Acta 1992, 1111:1-6.
53. Nishikawa K., Arai H., Inoue K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J. Biol. Chem. 1990, 265:5226-5231.
54. Bradley A.J., Brooks D.E., Norris-Jones R., Devine D.V. C1q binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14-26 of the human C1qA chain in a sequence independent manner. Biochim. Biophys. Acta 1999, 1418:19-30.
55. Chen H., Langer R., Edwards D.A. A film tension theory of phagocytosis. J. Colloid Interface Sci. 1997, 190:118-133.
56. Furumoto K., Ogawara K., Nagayama S., Takakura Y., Hashida M., Higaki K., Kimura T. Important role of serum proteins associated on the surface of particles in their hepatic disposition. J. Control. Release 2002, 83:89-96.
57. Juliano R.L., Stamp D., McCullough N. Pharmacokinetics of liposome-encapsulated antitumor drugs and implications for therapy. Ann. N. Y. Acad. Sci. 1978, 308:411-425.
58. Scheffel U., Rhodes B.A., Natarajan T.K., Wagner H.N. Albumin microspheres for study of the reticuloendothelial system. J. Nucl. Med. 1972, 13:498-503.
59. Sjöholm I., Edman P. Acrylic microspheres in vivo. I. Distribution and elimination of polyacrylamide microparticles after intravenous and intraperitoneal injection in mouse and rat. J. Pharmacol. Exp. Ther. 1979, 211:656-662.
60. Pasut G., Veronese F.M. State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release 2012, 161:461-472.
61. Ishida T., Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 2008, 354:56-62.
62. Dams E.T., Laverman P., Oyen W.J., Storm G., Scherphof G.L., van Der Meer J.W., Corstens F.H., Boerman O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 2000, 292:1071-1079.
63. Ishida T., Maeda R., Ichihara M., Mukai Y., Motoki Y., Manabe Y., Irimura K., Kiwada H. The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study. Cell. Mol. Biol. Lett. 2002, 7:286.
64. Tagami T., Uehara Y., Moriyoshi N., Ishida T., Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J. Control. Release 2011, 151:149-154.
65. Ishida T., Atobe K., Wang X., Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Release 2006, 115:251-258.
66. Tagami T., Nakamura K., Shimizu T., Yamazaki N., Ishida T., Kiwada H. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. J. Control. Release 2010, 142:160-166.
67. Renkin E.M. Filtration, diffusion, and molecular sieving through porous cellulose membranes. J. Gen. Physiol. 1954, 38:225-243.
68. Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 1990, 7:339-346.
69. Chau Y., Dang N.M., Tan F.E., Langer R. Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model. J. Pharm. Sci. 2006, 95:542-551.
70. Kratz F., Müller-Driver R., Hofmann I., Drevs J., Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem. 2000, 43:1253-1256.
71. Burger A.M., Hartung G., Stehle G., Sinn H., Fiebig H.H. Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int. J. Cancer 2001, 92:718-724.
72. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 1998, 89:307-314.
73. Loadman P.M., Bibby M.C., Double J.A., Al-Shakhaa W.M., Duncan R. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin. Cancer Res. 1999, 5:3682-3688.
74. Pechar M., Ulbrich K., Subr V., Seymour L.W., Schacht E.H. Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin. Bioconjug. Chem. 2000, 11:131-139.
75. Tomlinson R., Heller J., Brocchini S., Duncan R. Polyacetal-doxorubicin conjugates designed for pH-dependent degradation. Bioconjug. Chem. 2003, 14:1096-1106.
76. Kakinoki A., Kaneo Y., Tanaka T., Hosokawa Y. Synthesis and evaluation of water-soluble poly(vinyl alcohol)-paclitaxel conjugate as a macromolecular prodrug. Biol. Pharm. Bull. 2008, 31:963-969.
77. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., Boivin C., Hesslewood S., Twelves C., Blackie R., Schatzlein A., Jodrell D., Bissett D., Calvert H., Lind M., Robbins A., Burtles S., Duncan R., Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34:1629-1636.
78. Taurin S., Nehoff H., Greish K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?. J. Control. Release 2012, 164:265-275.
79. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 1988, 48:2641-2658.
80. Andresen T.L., Thompson D.H., Kaasgaard T. Enzyme-triggered nanomedicine: drug release strategies in cancer therapy. Mol. Membr. Biol. 2010, 27:353-363.
81. Fleige E., Quadir M.A., Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv. Drug Deliv. Rev. 2012, 64:866-884.
82. Bae Y.H., Park K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release 2011, 153:198-205.
83. Mahato R., Tai W., Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv. Drug Deliv. Rev. 2011, 63:659-670.
84. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 1999, 5:83-94.
85. Shiose Y., Ochi Y., Kuga H., Yamashita F., Hashida M. Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors. Biol. Pharm. Bull. 2007, 30:2365-2370.
86. Shiose Y., Kuga H., Ohki H., Ikeda M., Yamashita F., Hashida M. Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates. Bioconjug. Chem. 2009, 20:60-70.
87. Palermo C., Joyce J.A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 2008, 29:22-28.
88. Akamatsu K., Yamasaki Y., Nishikawa M., Takakura Y., Hashida M. Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E(1) using lactosylated poly(l-glutamic hydrazide) as a carrier. Biochem. Pharmacol. 2001, 62:1531-1536.
89. Kratz F., Beyer U., Schütte M.T. Drug-polymer conjugates containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carrier Syst. 1999, 16:245-288.
90. Yuan F., Quan L.D., Cui L., Goldring S.R., Wang D. Development of macromolecular prodrug for rheumatoid arthritis. Adv. Drug Deliv. Rev. 2012, 64:1205-1219.
91. Funk D., Schrenk H.H., Frei E. Development of a novel polyethylene glycol-corticosteroid-conjugate with an acid-cleavable linker. J. Drug Target. 2011, 19:434-445.
92. Lee C.C., Cramer A.T., Szoka F.C., Fréchet J.M. An intramolecular cyclization reaction is responsible for the in vivo inefficacy and apparent pH insensitive hydrolysis kinetics of hydrazone carboxylate derivatives of doxorubicin. Bioconjug. Chem. 2006, 17:1364-1368.
93. Nishida K., Mihara K., Takino T., Nakane S., Takakura Y., Hashida M., Sezaki H. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm. Res. 1991, 8:437-444.
94. Fujita T., Nishikawa M., Tamaki C., Takakura Y., Hashida M., Sezaki H. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. J. Pharmacol. Exp. Ther. 1992, 263:971-978.
95. Takakura Y., Mihara K., Hashida M. Control of the disposition profiles of proteins in the kidney via chemical modification. J. Control. Release 1994, 28:111-119.
96. Mihara K., Oka Y., Sawai K., Takakura Y., Hashida M. Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol. J. Drug Target. 1994, 2:317-321.
97. Nishikawa M., Hirabayashi H., Takakura Y., Hashida M. Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency. Pharm. Res. 1995, 12:209-214.
98. Nishikawa M., Miyazaki C., Yamashita F., Takakura Y., Hashida M. Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties. Am. J. Physiol. 1995, 268:G849-G856.
99. Yabe Y., Kobayashi N., Nishihashi T., Takahashi R., Nishikawa M., Takakura Y., Hashida M. Prevention of neutrophil-mediated hepatic ischemia/reperfusion injury by superoxide dismutase and catalase derivatives. J. Pharmacol. Exp. Ther. 2001, 298:894-899.
100. Higuchi Y., Nishikawa M., Kawakami S., Yamashita F., Hashida M. Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. Int. J. Pharm. 2004, 287:147-154.
101. Yabe Y., Koyama Y., Nishikawa M., Takakura Y., Hashida M. Hepatocyte-specific distribution of catalase and its inhibitory effect on hepatic ischemia/reperfusion injury in mice. Free Radic. Res. 1999, 30:265-274.
102. Yabe Y., Kobayashi N., Nishikawa M., Mihara K., Yamashita F., Takakura Y., Hashida M. Pharmacokinetics and preventive effects of targeted catalase derivatives on hydrogen peroxide-induced injury in perfused rat liver. Pharm. Res. 2002, 19:1815-1821.
103. Yamasaki Y., Sumimoto K., Nishikawa M., Yamashita F., Yamaoka K., Hashida M., Takakura Y. Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors. J. Pharmacol. Exp. Ther. 2002, 301:467-477.
104. Jansen R.W., Molema G., Ching T.L., Oosting R., Harms G., Moolenaar F., Hardonk M.J., Meijer D.K. Hepatic endocytosis of various types of mannose-terminated albumins. What is important, sugar recognition, net charge, or the combination of these features. J. Biol. Chem. 1991, 266:3343-3348.
105. Li H., Qian Z.M. Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 2002, 22:225-250.
106. Singh M. Transferrin As A targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des. 1999, 5:443-451.
107. Wu J., Nantz M.H., Zern M.A. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front. Biosci. 2002, 7:d717-d725.
108. Rensen P.C., de Vrueh R.L., Kuiper J., Bijsterbosch M.K., Biessen E.A., van Berkel T.J. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv. Drug Deliv. Rev. 2001, 47:251-276.
109. Bendas G. Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs 2001, 15:215-224.
110. Svensen N., Walton J.G., Bradley M. Peptides for cell-selective drug delivery. Trends Pharmacol. Sci. 2012, 33:186-192.
111. Marradi M., García I., Penadés S. Carbohydrate-based nanoparticles for potential applications in medicine. Prog. Mol. Biol. Transl. Sci. 2011, 104:141-173.
112. Jain K., Kesharwani P., Gupta U., Jain N.K. A review of glycosylated carriers for drug delivery. Biomaterials 2012, 33:4166-4186.
113. Yang L., Zhang X., Ye M., Jiang J., Yang R., Fu T., Chen Y., Wang K., Liu C., Tan W. Aptamer-conjugated nanomaterials and their applications. Adv. Drug Deliv. Rev. 2011, 63:1361-1370.
114. Levy-Nissenbaum E., Radovic-Moreno A.F., Wang A.Z., Langer R., Farokhzad O.C. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008, 26:442-449.
115. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 2009, 6:659-668.
116. Sankhala K.K., Mita A.C., Adinin R., Wood L., Beeram M., Bullock S., Yamagata N., Matsuno K., Fujisawa T., Phan A. A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J. Clin. Oncol. 2009, 27:S15.
117. Nel A.E., Mädler L., Velegol D., Xia T., Hoek E.M., Somasundaran P., Klaessig F., Castranova V., Thompson M. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 2009, 8:543-557.
118. Decuzzi P., Ferrari M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 2007, 28:2915-2922.
119. Gao H., Shi W., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9469-9474.
120. Murao A., Nishikawa M., Managit C., Wong J., Kawakami S., Yamashita F., Hashida M. Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition. Pharm. Res. 2002, 19:1808-1814.
121. Managit C., Kawakami S., Yamashita F., Hashida M. Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. J. Pharm. Sci. 2005, 94:2266-2275.
122. Kawakami S., Wong J., Sato A., Hattori Y., Yamashita F., Hashida M. Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochim. Biophys. Acta 2000, 1524:258-265.
123. Pirollo K.F., Chang E.H. Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol. 2008, 26:552-558.
124. Bae Y.H. Drug targeting and tumor heterogeneity. J. Control. Release 2009, 133:2-3.
125. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66:6732-6740.
126. Bae Y., Nishiyama N., Kataoka K. In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. Bioconjug. Chem. 2007, 18:1131-1139.
127. Trédan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
128. Kawabata K., Takakura Y., Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 1995, 12:825-830.